140 related articles for article (PubMed ID: 15170165)
1. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy.
Blijlevens NM; Lutgens LC; Schattenberg AV; Donnelly JP
Bone Marrow Transplant; 2004 Aug; 34(3):193-6. PubMed ID: 15170165
[TBL] [Abstract][Full Text] [Related]
2. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests.
Lutgens LC; Blijlevens NM; Deutz NE; Donnelly JP; Lambin P; de Pauw BE
Cancer; 2005 Jan; 103(1):191-9. PubMed ID: 15573372
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients.
Blijlevens NM; Donnelly JP; DePauw BE
Bone Marrow Transplant; 2005 Oct; 36(8):703-7. PubMed ID: 16062174
[TBL] [Abstract][Full Text] [Related]
4. Plasma citrulline level as a biomarker for cancer therapy-induced small bowel mucosal damage.
Barzał JA; Szczylik C; Rzepecki P; Jaworska M; Anuszewska E
Acta Biochim Pol; 2014; 61(4):615-31. PubMed ID: 25473654
[TBL] [Abstract][Full Text] [Related]
5. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients.
Lutgens LC; Deutz N; Granzier-Peeters M; Beets-Tan R; De Ruysscher D; Gueulette J; Cleutjens J; Berger M; Wouters B; von Meyenfeldt M; Lambin P
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):275-85. PubMed ID: 15337566
[TBL] [Abstract][Full Text] [Related]
6. Plasma citrulline as a quantitative biomarker of HIV-associated villous atrophy in a tropical enteropathy population.
Papadia C; Kelly P; Caini S; Corazza GR; Shawa T; Franzè A; Forbes A; Di Sabatino A
Clin Nutr; 2010 Dec; 29(6):795-800. PubMed ID: 20646802
[TBL] [Abstract][Full Text] [Related]
7. Serum citrulline is a simple quantitative marker for small intestinal enterocytes mass and absorption function in short bowel patients.
Jianfeng G; Weiming Z; Ning L; Fangnan L; Li T; Nan L; Jieshou L
J Surg Res; 2005 Aug; 127(2):177-82. PubMed ID: 15921697
[TBL] [Abstract][Full Text] [Related]
8. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction.
Crenn P; Messing B; Cynober L
Clin Nutr; 2008 Jun; 27(3):328-39. PubMed ID: 18440672
[TBL] [Abstract][Full Text] [Related]
9. Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients.
Herbers AH; Blijlevens NM; Donnelly JP; de Witte TJ
Bone Marrow Transplant; 2008 Sep; 42(5):345-9. PubMed ID: 18587437
[TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant.
Blijlevens NM; Donnelly JP; de Pauw BE
Bone Marrow Transplant; 2005 Apr; 35(7):707-11. PubMed ID: 15785771
[TBL] [Abstract][Full Text] [Related]
11. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation.
Papadia C; Sherwood RA; Kalantzis C; Wallis K; Volta U; Fiorini E; Forbes A
Am J Gastroenterol; 2007 Jul; 102(7):1474-82. PubMed ID: 17459021
[TBL] [Abstract][Full Text] [Related]
12. Citrulline and the gut.
Curis E; Crenn P; Cynober L
Curr Opin Clin Nutr Metab Care; 2007 Sep; 10(5):620-6. PubMed ID: 17693747
[TBL] [Abstract][Full Text] [Related]
13. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic stem-cell transplant recipients.
Derikx JP; Blijlevens NM; Donnelly JP; Fujii H; Kanda T; van Bijnen AA; Heineman E; Buurman WA
Ann Oncol; 2009 Feb; 20(2):337-42. PubMed ID: 18725393
[TBL] [Abstract][Full Text] [Related]
14. Plasma citrulline is a marker of absorptive small bowel length in patients with transient enterostomy and acute intestinal failure.
Picot D; Garin L; Trivin F; Kossovsky MP; Darmaun D; Thibault R
Clin Nutr; 2010 Apr; 29(2):235-42. PubMed ID: 19744750
[TBL] [Abstract][Full Text] [Related]
15. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease.
Crenn P; Vahedi K; Lavergne-Slove A; Cynober L; Matuchansky C; Messing B
Gastroenterology; 2003 May; 124(5):1210-9. PubMed ID: 12730862
[TBL] [Abstract][Full Text] [Related]
16. Poor diagnostic accuracy of a single fasting plasma citrulline concentration to assess intestinal energy absorption capacity.
Peters JH; Wierdsma NJ; Teerlink T; van Leeuwen PA; Mulder CJ; van Bodegraven AA
Am J Gastroenterol; 2007 Dec; 102(12):2814-9. PubMed ID: 17764491
[TBL] [Abstract][Full Text] [Related]
17. Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
van Vliet MJ; Tissing WJ; Rings EH; Koetse HA; Stellaard F; Kamps WA; de Bont ES
Pediatr Blood Cancer; 2009 Dec; 53(7):1188-94. PubMed ID: 19688831
[TBL] [Abstract][Full Text] [Related]
18. Role and significance of plasma citrulline in the early phase after small bowel transplantation in pigs.
Nadalin S; Biglarnia AR; Testa G; Koppara TR; Schaffer R; Johnson C; Toetsch M; Broelsch CE; Malagó M
Transpl Int; 2007 May; 20(5):425-31. PubMed ID: 17313447
[TBL] [Abstract][Full Text] [Related]
19. Trends in serum citrulline and acute rejection among recipients of small bowel transplants.
Pappas PA; Tzakis AG; Saudubray JM; Gaynor JJ; Carreno MR; Huijing F; Kleiner G; Rabier D; Kato T; Levi DM; Nishida S; Gelman B; Thompson JF; Mittal N; Ruiz P
Transplant Proc; 2004 Mar; 36(2):345-7. PubMed ID: 15050154
[TBL] [Abstract][Full Text] [Related]
20. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation.
David AI; Selvaggi G; Ruiz P; Gaynor JJ; Tryphonopoulos P; Kleiner GI; Moon JI; Nishida S; Pappas PA; Conanan L; Weppler D; Esquenazi V; Levi DM; Kato T; Tzakis AG
Transplantation; 2007 Nov; 84(9):1077-81. PubMed ID: 17998860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
